Skip to main content
HCPCS J9206 · Level II · Part B drug

J9206: irinotecan (Camptosar), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9206

Billing unit
20 MG
Irinotecan injection
ASP payment limit
$1.569
October 2026; -15.2% vs July 2026
Practitioner MUE
42
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9206 is the Level II code for Injection, irinotecan, 20 mg, billed per 20 MG. The Medicare Part B ASP payment limit for October 2026 is $1.569 per billing unit, down 15.2% from July 2026. The practitioner MUE allows up to 42 units per date of service (MAI 3), so a full 42-unit day is $65.90 at the current limit. Under OPPS it carries status indicator N. J9206 is billed in units of 20 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 31 NDCs to it, sold as Camptosar, Irinotecan HCl by Pfizer Inc, Hikma Pharmaceuticals USA Inc., Northstar RxLLC. No current Billing and Coding Article lists J9206, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9206 at $1.569 per 20 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $1.851 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9206
QuarterPayment limitPerCoinsurance
October 2026$1.56920 MG20%
July 2026$1.85120 MG—
CMS note: AMP-based payment limit

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 31 NDCs from 11 labelers to J9206. Report the NDC in the claim's drug segment and bill the number of J9206 units that equals the quantity administered divided by 20 MG; the last column gives units per full package.

NDCs that crosswalk to J9206
NDCDrug nameLabelerPackage sizeBilling units / package
00009-0082-02CamptosarPfizer Inc15 × 115
00009-0112-05CamptosarPfizer Inc5 × 15
00009-7529-03CamptosarPfizer Inc5 × 15
00009-7529-04CamptosarPfizer Inc2 × 12
00009-7529-05CamptosarPfizer Inc15 × 115
00009-7529-10CamptosarPfizer Inc2 × 12
00143-9701-01Irinotecan HClHikma Pharmaceuticals USA Inc.5 × 15
00143-9702-01Irinotecan HClHikma Pharmaceuticals USA Inc.2 × 12
16714-0027-01Irinotecan HClNorthstar RxLLC2 × 12
16714-0131-01Irinotecan HClNorthstar RxLLC5 × 15
25021-0230-02Irinotecan HClSagent Pharmaceuticals2 × 12
25021-0230-05Irinotecan HClSagent Pharmaceuticals5 × 15
45963-0614-51Irinotecan HClActavis Pharma, Inc.2 × 12
45963-0614-55Irinotecan HClActavis Pharma, Inc.5 × 15
50742-0401-02Irinotecan HClIngenus Pharmaceuticals LLC2 × 12
50742-0402-05Irinotecan HClIngenus Pharmaceuticals LLC5 × 15
55150-0352-01Irinotecan HClEugia US LLC2 × 12
55150-0353-01Irinotecan HClEugia US LLC5 × 15
55150-0354-01Irinotecan HClEugia US LLC15 × 115
60505-6128-00Irinotecan HClApotex Corp2 × 12
60505-6128-01Irinotecan HClApotex Corp5 × 15
60505-6272-01Irinotecan HClApotex Corp5 × 15
61703-0349-09Irinotecan HClPfizer Inc5 × 15
61703-0349-16Irinotecan HClPfizer Inc2 × 12
61703-0349-36Irinotecan HClPfizer Inc25 × 125
63323-0193-52Irinotecan HClFreseniUS Kabi USA, LLC2 × 12
63323-0193-55Irinotecan HClFreseniUS Kabi USA, LLC5 × 15
68001-0480-22Irinotecan HClBluePoint Laboratories5 × 15
68001-0480-35Irinotecan HClBluePoint Laboratories2 × 12
70700-0169-22Irinotecan HClXiromed, LLC2 × 12
70700-0170-22Irinotecan HClXiromed, LLC5 × 15

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9206. For practitioners the limit is 42 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9206 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services423 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital423 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J9206 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9206 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9206 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9206 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9206 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9206 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9206 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J9206 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9206

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9206

What does HCPCS code J9206 describe?

J9206 is defined by CMS as "Injection, irinotecan, 20 mg". Each billing unit represents 20 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9206 a CPT code?

No. J9206 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as irinotecan (Camptosar); CPT codes are five-character codes maintained by the AMA. On a Part B claim J9206 reports the drug itself in 20 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9206 in October 2026?

The ASP-based payment limit is $1.569 per 20 MG, with 20% beneficiary coinsurance. The July 2026 limit was $1.851. Commercial payers use their own fee schedules.

How many units of J9206 can be billed per day?

The practitioner Medically Unlikely Edit is 42 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J9206?

The October 2026 ASP crosswalk lists 31 NDCs from 11 labelers: Camptosar (Pfizer Inc); Irinotecan HCl (Hikma Pharmaceuticals USA Inc.); Irinotecan HCl (Northstar RxLLC); Irinotecan HCl (Sagent Pharmaceuticals). For example NDC 00009-0082-02 (package size 15) equals 15 billing units of J9206.

Does J9206 have NCCI bundling edits?

No active practitioner PTP pairs list J9206 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.